Hong Suk Song
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hong Suk Song has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
Young Rok Do
Department of Internal Medicine, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea
9 shared publicationsJin Young Kim
Department of Internal Medicine, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea
5 shared publicationsKeon Uk Park
Department of Internal Medicine, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea
5 shared publicationsHun Mo Ryoo
Daegu Catholic University Medical Center Department of Oncology and Hematology Daegu South Korea
4 shared publicationsJin Ho Baek
Ulsan University Hospital Division of Hematology‐Oncology Ulsan South Korea
4 shared publicationsKyung Hee Lee
Yeungnam University Hospital
4 shared publications
Latest Publications
- 1 December 2013
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 14 (12) , 1866-1872
Noninterventional Observational Study Using High-Dose Controlled-Release Oxycodone (CR Oxycodone) for Cancer Pain Management in Outpatient Clinics
Efficacy, safety, and quality of life (QoL) for patients receiving larger doses of controlled‐release oxycodone (CR oxycodone) in outpatient clinics are evaluated.
- 1 December 2013
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 14 (12) , 1866-1872
Noninterventional Observational Study Using High-Dose Controlled-Release Oxycodone (CR Oxycodone) for Cancer Pain Management in Outpatient Clinics
Efficacy, safety, and quality of life (QoL) for patients receiving larger doses of controlled‐release oxycodone (CR oxycodone) in outpatient clinics are evaluated.
- Open Access
- 1 January 2013
- Published by Korean Association of Internal Medicine in The Korean Journal of Medicine
- Vol. 85 (5) , 535-539
Gastrointestinal Stromal Tumors in a Patient with Neurofibromatosis Type 1
- 1 January 2013
- Published by Korean Association of Internal Medicine in The Korean Journal of Medicine
- Vol. 85 (5) , 535-539
Open AccessGastrointestinal Stromal Tumors in a Patient with Neurofibromatosis Type 1
- Open Access
- 1 September 2012
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 44 (3) , 173-178
Metachronous Double Primary Cancer after Diagnosis of Gastric Cancer
Kim JY, et al. Cancer Res Treat. 2012 Sep;44(3):173-178. http://dx.doi.org/10.4143/crt.2012.44.3.173
- 1 September 2012
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 44 (3) , 173-178
Open AccessMetachronous Double Primary Cancer after Diagnosis of Gastric Cancer
Kim JY, et al. Cancer Res Treat. 2012 Sep;44(3):173-178. http://dx.doi.org/10.4143/crt.2012.44.3.173
- 9 July 2012
- Published by SAGE Publications in American Journal of Hospice and Palliative Medicine®
- Vol. 30 (4) , 393-398
Prevalence and Management of Pain by Different Age Groups of Korean Cancer Patients
The aims of this study were to evaluate the differences in cancer prevalence and pain management between young and elderly patients. The patients were grouped into 3 groups. The prevalence of cancer pain was 50.0% in those younger than 65 years, 55.9% in those aged between 65 and 75, and 58.3% in those older than 75 years. The prevalence of cancer pain was higher for patients in advanced stages and with poor performance status. Using logistic regression analysis, we found that performance status has a significant correlation with cancer pain. Severe cancer pain occurred in 8.0% of the patient and was most prevalent in the advanced stage. Side effects of analgesics were observed in 24.5%. Cancer pain correlates with performance status and cancer stage but not significantly with age.
- 9 July 2012
- Published by SAGE Publications in American Journal of Hospice and Palliative Medicine®
- Vol. 30 (4) , 393-398
Prevalence and Management of Pain by Different Age Groups of Korean Cancer Patients
The aims of this study were to evaluate the differences in cancer prevalence and pain management between young and elderly patients. The patients were grouped into 3 groups. The prevalence of cancer pain was 50.0% in those younger than 65 years, 55.9% in those aged between 65 and 75, and 58.3% in those older than 75 years. The prevalence of cancer pain was higher for patients in advanced stages and with poor performance status. Using logistic regression analysis, we found that performance status has a significant correlation with cancer pain. Severe cancer pain occurred in 8.0% of the patient and was most prevalent in the advanced stage. Side effects of analgesics were observed in 24.5%. Cancer pain correlates with performance status and cancer stage but not significantly with age.
- Open Access
- 1 January 2012
- Published by Korean Association of Internal Medicine in The Korean Journal of Medicine
- Vol. 82 (1) , 35-36
FOLFOX-4 Combination Chemotherapy as a First-line Treatment in Patients with Advanced Gastric Cancer
- 1 January 2012
- Published by Korean Association of Internal Medicine in The Korean Journal of Medicine
- Vol. 82 (1) , 35-36
Open AccessFOLFOX-4 Combination Chemotherapy as a First-line Treatment in Patients with Advanced Gastric Cancer
- 12 May 2010
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 67 (3) , 527-532
Multicenter phase II trial of S-1, paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer
The present study was conducted to evaluate the efficacy and safety of a combination regimen of S-1, paclitaxel plus cisplatin in patients with advanced gastric cancer. Patients with previously untreated metastatic or recurrent, measurable gastric cancer received intravenous paclitaxel 80 mg/m2 plus cisplatin 30 mg/m2 on days 1, 8 and S-1 35 mg/m2 orally twice daily on days 1–14 based on a 3-week cycle. Forty-four patients were enrolled in the current study, among whom 38 were assessable for efficacy and all assessable for toxicity. Two complete response and 24 partial responses were confirmed, giving an overall response rate of 59.1%. At a median follow-up of 11.4 months, the median time to progression and median overall survival was 9.4 (95% CI 6.8–12.1) months and 11.2 (95% CI 7.6–14.8) months, respectively. Grade 3/4 neutropenia occurred in 45 events (20.9%) and febrile neutropenia was observed in five events (2.3%). The common non-hematologic toxicity was nausea (grade 1/2, 27.2%) and diarrhea (grade 1/2, 9.0%). The combination of S-1, paclitaxel and cisplatin was found to be well tolerated and effective in patients with advanced gastric cancer.
- 12 May 2010
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 67 (3) , 527-532
Multicenter phase II trial of S-1, paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer
The present study was conducted to evaluate the efficacy and safety of a combination regimen of S-1, paclitaxel plus cisplatin in patients with advanced gastric cancer. Patients with previously untreated metastatic or recurrent, measurable gastric cancer received intravenous paclitaxel 80 mg/m2 plus cisplatin 30 mg/m2 on days 1, 8 and S-1 35 mg/m2 orally twice daily on days 1–14 based on a 3-week cycle. Forty-four patients were enrolled in the current study, among whom 38 were assessable for efficacy and all assessable for toxicity. Two complete response and 24 partial responses were confirmed, giving an overall response rate of 59.1%. At a median follow-up of 11.4 months, the median time to progression and median overall survival was 9.4 (95% CI 6.8–12.1) months and 11.2 (95% CI 7.6–14.8) months, respectively. Grade 3/4 neutropenia occurred in 45 events (20.9%) and febrile neutropenia was observed in five events (2.3%). The common non-hematologic toxicity was nausea (grade 1/2, 27.2%) and diarrhea (grade 1/2, 9.0%). The combination of S-1, paclitaxel and cisplatin was found to be well tolerated and effective in patients with advanced gastric cancer.
- 18 September 2009
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 66 (1) , 31-36
A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer
The objective of this study was to evaluate the efficacy and toxicity of docetaxel and cisplatin combination chemotherapy in patients with metastatic esophageal cancer. Patients with untreated metastatic squamous cell esophageal cancer, which was histologically proven with at least one measurable lesion, were eligible for the study. Docetaxel 70 mg/m2 and cisplatin 70 mg/m2 were intravenously given on day 1 of 21 days schedule. From December 2004 to December 2007, total of 39 patients (M/F = 39/0) were enrolled. The median age was 65 years. Thirty-four patients were evaluable for response. There were 3 (7.7%) complete remission, 10 (25.6%) partial remission, 11 (28.2%) stable disease, and 10 (25.6%) progression disease. The objective tumor response rate was 33.3% in intention-to-treat (ITT). Median PFS was 5.0 months and median survival was 8.3 months. Median number of cycles administered was 3. The relative dose intensity of docetaxel and cisplatin was 92 and 91%, respectively. This treatment was comparatively tolerated with grade 3/4 neutropenia in 20.5%/10.3%, grade 3 infection in 2.6% of patients. Docetaxel plus cisplatin combination chemotherapy showed promising antitumor activity with manageable toxicities in patients with metastatic squamous esophageal cancer.
- 18 September 2009
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 66 (1) , 31-36
A multi-center phase II study of docetaxel plus cisplatin as first-line therapy in patients with metastatic squamous cell esophageal cancer
The objective of this study was to evaluate the efficacy and toxicity of docetaxel and cisplatin combination chemotherapy in patients with metastatic esophageal cancer. Patients with untreated metastatic squamous cell esophageal cancer, which was histologically proven with at least one measurable lesion, were eligible for the study. Docetaxel 70 mg/m2 and cisplatin 70 mg/m2 were intravenously given on day 1 of 21 days schedule. From December 2004 to December 2007, total of 39 patients (M/F = 39/0) were enrolled. The median age was 65 years. Thirty-four patients were evaluable for response. There were 3 (7.7%) complete remission, 10 (25.6%) partial remission, 11 (28.2%) stable disease, and 10 (25.6%) progression disease. The objective tumor response rate was 33.3% in intention-to-treat (ITT). Median PFS was 5.0 months and median survival was 8.3 months. Median number of cycles administered was 3. The relative dose intensity of docetaxel and cisplatin was 92 and 91%, respectively. This treatment was comparatively tolerated with grade 3/4 neutropenia in 20.5%/10.3%, grade 3 infection in 2.6% of patients. Docetaxel plus cisplatin combination chemotherapy showed promising antitumor activity with manageable toxicities in patients with metastatic squamous esophageal cancer.
- Open Access
- 22 January 2008
- Published by Springer Nature in British Journal of Cancer
- Vol. 98 (3) , 542-546
Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group
The present study was conducted to evaluate the efficacy and safety of a combination regimen of docetaxel plus oxaliplatin in patients with advanced gastric cancer. Patients with previously untreated metastatic or recurrent, measurable gastric cancer received intravenous docetaxel 65 mg m−2 plus oxaliplatin 120 mg m−2 on day 1 based on a 3-week cycle. Forty-two patients were enrolled in the current study, among whom 39 were assessable for efficacy and all assessable for toxicity. One complete response and 18 partial responses were confirmed, giving an overall response rate of 45.2% (95% confidence interval (CI); 31.7–59.7%). At a median follow-up of 7.7 months, the median time to progression and median overall survival was 5.7 (95% CI; 4.3–7.2) months and 9.9 (95% CI; 7.8–12.0) months, respectively. Grade 3/4 neutropenia occurred in 11 patients (26.1%) and febrile neutropenia was observed in four patients (9.5%). The common non-haematologic toxicity was fatigue (grade 1/2, 61.9%) and nausea (grade 1/2, 47.7%). The combination of docetaxel and oxaliplatin was found to be well tolerated and effective in patients with advanced gastric cancer.
- 22 January 2008
- Published by Springer Nature in British Journal of Cancer
- Vol. 98 (3) , 542-546
Open AccessMulticenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group
The present study was conducted to evaluate the efficacy and safety of a combination regimen of docetaxel plus oxaliplatin in patients with advanced gastric cancer. Patients with previously untreated metastatic or recurrent, measurable gastric cancer received intravenous docetaxel 65 mg m−2 plus oxaliplatin 120 mg m−2 on day 1 based on a 3-week cycle. Forty-two patients were enrolled in the current study, among whom 39 were assessable for efficacy and all assessable for toxicity. One complete response and 18 partial responses were confirmed, giving an overall response rate of 45.2% (95% confidence interval (CI); 31.7–59.7%). At a median follow-up of 7.7 months, the median time to progression and median overall survival was 5.7 (95% CI; 4.3–7.2) months and 9.9 (95% CI; 7.8–12.0) months, respectively. Grade 3/4 neutropenia occurred in 11 patients (26.1%) and febrile neutropenia was observed in four patients (9.5%). The common non-haematologic toxicity was fatigue (grade 1/2, 61.9%) and nausea (grade 1/2, 47.7%). The combination of docetaxel and oxaliplatin was found to be well tolerated and effective in patients with advanced gastric cancer.
- 3 January 2008
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 62 (5) , 763-768
A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer
- 3 January 2008
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 62 (5) , 763-768
A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer
- 27 February 2007
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 60 (6) , 863-869
Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer
- 27 February 2007
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 60 (6) , 863-869
Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer